In a $10-million cash deal, Acorda Therapeutics Inc. in Hawthorne will merge its drug development subsidiary into a privately held pharmaceutical company that is developing a nasal spray treatment for seizures.
In a $10-million cash deal, Acorda Therapeutics Inc. in Hawthorne will merge its drug development subsidiary into a privately held pharmaceutical company that is developing a nasal spray treatment for seizures.